ClinicalTrials.govpublic full text
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
lung cancer, cancer, non-small-cell lung cancer, adenocarcinoma, egfr gene mutation, chemotherapy, pemetrexed, erlotinib, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 885547
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.